Research ArticleAccepted Article
The effect of creatine supplementation on muscle function in childhood myositis: A randomized, double-blind, placebo-controlled feasibility study
Saunya Dover, Samantha Stephens, Jane E. Schneiderman, Eleanor Pullenayegum, Greg D. Wells, Deborah M. Levy, Jo-Anne Marcuz, Kristi Whitney, Andreas Schulze, Ingrid Tein and Brian M. Feldman
The Journal of Rheumatology August 2020, jrheum.191375; DOI: https://doi.org/10.3899/jrheum.191375
Saunya Dover
From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.
Samantha Stephens
From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.
Jane E. Schneiderman
From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.
Eleanor Pullenayegum
From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.
Greg D. Wells
From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.
Deborah M. Levy
From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.
Jo-Anne Marcuz
From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.
Kristi Whitney
From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.
Andreas Schulze
From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.
Ingrid Tein
From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.
Brian M. Feldman
From Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON; Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON; Clinical Research Services, Research Institute, The Hospital for Sick Children, Toronto, ON; Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON; Institute of Health Policy, Management & Evaluation, the Dalla Lana School of Public Health, University of Toronto, Toronto, ON; Translational Medicine, The Hospital for Sick Children, Toronto, ON; Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, ON; Division of Neurology, Dept. of Pediatrics and Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON; Division of Rheumatology, The Hospital for Sick Children, Toronto, ON; Department of Rehabilitation, The Hospital for Sick Children, Toronto, ON. Funding for this work was provided by The Pedano Family Juvenile Dermatomyositis Research Grant of The Myositis Association and The Rare Disease Foundation. Study drugs were supplied by AlzChem. The funders were not involved in any aspects of study design, data collection, data analysis or interpretation, writing of the report or the decision to publish the report. A Schulze reports grants from Aglea BioTherapeutics during the conduct of the study. I Tein reports grants from Myositis Association during the conduct of the study; grants from Foundation for Prader Willi Research, grants from Cure JM Foundation, grants from Connaught Global Challenge Award, University of Toronto, grants from CIHR Planning and Dissemination Grant outside the submitted work. The remaining authors have no conflicts to disclose. Address correspondence to Brian M. Feldman, The Hospital for Sick Children Research Institute, 555 University Ave, Toronto, ON, Canada M5G 1X8. Email: brian.feldman@sickkids.ca.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Accepted manuscript
The effect of creatine supplementation on muscle function in childhood myositis: A randomized, double-blind, placebo-controlled feasibility study
Saunya Dover, Samantha Stephens, Jane E. Schneiderman, Eleanor Pullenayegum, Greg D. Wells, Deborah M. Levy, Jo-Anne Marcuz, Kristi Whitney, Andreas Schulze, Ingrid Tein, Brian M. Feldman
The Journal of Rheumatology Aug 2020, jrheum.191375; DOI: 10.3899/jrheum.191375
Accepted manuscript
The effect of creatine supplementation on muscle function in childhood myositis: A randomized, double-blind, placebo-controlled feasibility study
Saunya Dover, Samantha Stephens, Jane E. Schneiderman, Eleanor Pullenayegum, Greg D. Wells, Deborah M. Levy, Jo-Anne Marcuz, Kristi Whitney, Andreas Schulze, Ingrid Tein, Brian M. Feldman
The Journal of Rheumatology Aug 2020, jrheum.191375; DOI: 10.3899/jrheum.191375